December 2013

**Ulipristal acetate (Esmya®) 5mg Tablets for the treatment of moderate to severe symptoms of uterine fibroids prior to surgery**

The Interface Prescribing and New Therapies Subgroup discussed the above at its meeting on the 17th December 2013. The recommendation of this subgroup is as follows:*  

The New Therapies Subgroup of the GMMMGG considered the use of Ulipristal (Esmya®▼) for the treatment of moderate to severe symptoms of uterine fibroids prior to surgery.

The group recommends ulipristal acetate (Esmya®) as an option for treatment in the above indication.

It is recommended that prescribing is retained within secondary care for the full treatment duration and that ulipristal 5mg tablets should be prescribed by the surgeon responsible for arranging the surgery or as per locally agreed care pathways. Local discussions will need to take place to ensure this happens in practice.

Prescribers are reminded that there are two products containing ulipristal available and the strength of tablets prescribed and duration of treatment should be clarified prior to prescribing.

According to set criteria Esmya® was deemed to be a medium priority for funding.

Review date: December 2015

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.